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Abstract
Background: EarlyR gene signature in estrogen receptor–positive (ERþ) breast cancer is computed from the expression values
of ESPL1, SPAG5, MKI67, PLK1, and PGR. EarlyR has been validated in multiple cohorts profiled using microarrays. This study
sought to verify the prognostic features of EarlyR in a case-cohort sample from BIG 1–98, a randomized clinical trial of ERþ
postmenopausal breast cancer patients treated with adjuvant endocrine therapy (letrozole or tamoxifen).
Methods: Expression of EarlyR gene signature was estimated by Illumina cDNA-mediated Annealing, Selection, and Ligation assay
of RNA from formalin-fixed, paraffin-embedded primary breast cancer tissues in a case-cohort subset of ERþ women (N¼1174;
216 cases of recurrence within 8 years) from BIG 1–98. EarlyR score and prespecified risk strata (25¼ low, 26–75¼ intermediate,
>75¼high) were “blindly” computed. Analysis endpoints included distant recurrence–free interval and breast cancer–free interval
at 8 years after randomization. Hazard ratios (HRs) and test statistics were estimated with weighted analysis methods.
Results: The distribution of the EarlyR risk groups was 67% low, 19% intermediate, and 14% high risk in this ERþ cohort.
EarlyR was prognostic for distant recurrence–free interval; EarlyR high-risk patients had statistically increased risk of distant
recurrence within 8 years (HR¼1.73, 95% confidence interval ¼ 1.14 to 2.64) compared with EarlyR low-risk patients. EarlyR
was also prognostic of breast cancer–free interval (HR¼1.74, 95% confidence interval ¼ 1.21 to 2.62).
Conclusions: This study confirmed the prognostic significance of EarlyR using RNA from formalin-fixed, paraffin-embedded
tissues from a case-cohort sample of BIG 1–98. EarlyR identifies a set of high-risk patients with relatively poor prognosis who
may be considered for additional treatment. Further studies will focus on analyzing the predictive value of EarlyR signature.
Selection of an effective treatment regimen for a primary breast
cancer patient must take into account the molecular heteroge-
neity of the disease. Approximately 80% of primary breast
cancers are estrogen receptor–positive (ERþ), almost all of
which are treated with endocrine therapy. Although prognosis
for early-stage ERþ breast cancer patients treated with
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endocrine therapy alone is considered “good,” at least 20% of
patients will suffer a distant recurrence within 10 years.
Traditionally, clinical factors such as tumor size, grade, number
of positive lymph nodes, and indicators of proliferation such as
Ki67 have been used to assess the utility of adjuvant chemo-
therapy. However, these factors alone fail to define all molecu-
lar traits that have a considerable effect on prognosis. There is a
considerable clinical need for a molecular assay that can differ-
entiate between the small percentage of ERþ breast cancer
patients who have high risk of relapse and may benefit from
chemotherapy and the majority who can safely avoid it.
Multi-gene signatures such as Oncotype DX Recurrence
Score (1), Mammaprint (2,3), Risk of Recurrence (ROR) (4), Breast
Cancer Index (5), and EndoPredict (6) are increasingly being
used to guide treatment decisions. Each test has its advantages
and limitations.
To address the limitations of the current assays, we devel-
oped the EarlyR gene signature based on the expression of
ESPL1, SPAG5, MKI67, PLK1, and PGR [Supplementary Methods,
available online; Buechler et al. (7–9)]. EarlyR can be applied as a
continuous score (0–100) or as discrete risk strata (low, interme-
diate, and high risk). EarlyR has been shown (9) to be prognostic
of distant recurrence within 8 years of diagnosis in multiple
cohorts with gene expression measured by Affymetrix microar-
rays and in the Illumina-assayed Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC) cohort
(10). In the ERþ METABRIC cohort (N¼ 1518), in particular,
EarlyR continuous score and risk strata were statistically signifi-
cantly prognostic of distant recurrence–free interval (DRFI) and
breast cancer–free interval (BCFI), up to 8 years post-diagnosis
(hazard ratio [HR] of EarlyR-High to EarlyR-Low for DRFI is 2.6
[95% confidence interval [CI] ¼ 2.0 to 3.3] in ERþ overall), and
subgroups of lymph node–negative (LN), lymph node–positive
(LNþ), and HER2 negative patients (9). Importantly, in all of
these subgroups, EarlyR classified at least 65% of patients as
low risk and fewer than 20% as intermediate risk. EarlyR
has also been shown to predict response to neoadjuvant che-
motherapy (11). We showed that EarlyR-High patients who
received neoadjuvant chemotherapy and endocrine therapy
had lower risk of recurrence than EarlyR-High patients treated
only with endocrine therapy. In contrast, EarlyR-Low patients
did not benefit from adding chemotherapy to endocrine
therapy.
In most previous studies of EarlyR, gene expression was mea-
sured from frozen tissues collected from patient cohorts of con-
venience, limiting its clinical applicability. Additionally, these
patients may not have been treated with regimens that consti-
tute current standard of care. Validation of the prognostic signifi-
cance of EarlyR in a contemporary, well-annotated, randomized,
controlled clinical trial is needed. The current study aims to as-
sess the prognostic significance of EarlyR using a cohort of
patients from the randomized, controlled BIG 1–98 clinical trial of
endocrine therapy for postmenopausal women with hormone
receptor–positive early breast cancer (12).
Patients and Methods
Study (EarlyR) Cohort
Between March 1998 and May 2003, 8010 postmenopausal
women with hormone receptor–positive operable invasive
breast cancer were randomly assigned to monotherapy with
letrozole or tamoxifen for 5 years, a sequential strategy of
letrozole for 2 years followed by tamoxifen for 3 years, or the re-
verse sequence (ClinicalTrials.gov NCT00004205). At the
protocol-specified update 12 years after trial commencement,
and with a median follow-up of 8.1 years, 1022 distant recur-
rences were observed (12). Chemotherapy treatment was at the
discretion of individual physicians and patients.
Between 1998 and 2010, the International Breast Cancer Study
Group (IBCSG) carried out retrospective tissue collection in accor-
dance with institutional guidelines and national laws. Formalin-
fixed, paraffin-embedded (FFPE) primary breast cancer tissue
blocks were assessed for availability of invasive tumor material
for translational research under the approval of the IBCSG
Biological Protocols Working Group. All material processing and
assaying was done without knowledge of patients’ treatment
assignments or outcomes. Appropriate permissions from the
University of Notre Dame and Indiana University institutional re-
view boards were also obtained for use of the samples and data.
A case-cohort sampling design was used to select 1218 FFPE
tissue samples (DASL cohort; 257 cases of recurrence) for whole-
genome profiling using the DASL protocol on the Illumina HT-
12 v4 microarray as follows. All breast cancer recurrence cases
(ie, BCFI events) with available RNA were included, and nonre-
currence cases were sampled according to four stratification
factors, resulting in 48 strata (classes). There were differences in
the proportion of nonrecurrence patients sampled by the four
stratification factors: (1) two geographic regions; (2) treatment
arms and randomization option, resulting in six groups; (3)
lymph node status (positive, negative/unknown); and (4) prior
chemotherapy use (no, yes). The sampling fractions were the
number of cases selected for DASL analysis divided by the num-
ber of BIG 1–98 RNA samples in each of these 48 groups. The
weights were the inverses of the sampling fractions.
The EarlyR cohort (N¼ 1174; Figure 1) consists of all samples
from the DASL cohort (N¼ 1218) that were centrally confirmed
to be ERþ (1% ER expression by immunohistochemistry). The
prognostic significance of EarlyR was also analyzed in three
subcohorts of ERþ/LN (N¼ 547), ERþ/LNþ (N¼ 610), and ERþ/
HER2 (N¼ 1098) patients, where centrally assessed ER (positive
is 1% immunostained cells), HER2 status (positive if amplified
by fluorescent in situ hybridization (FISH) or a few cases that
were 3þ by immunohistochemistry without fluorescent in situ
hybridization assessment), and lymph node status were used to
define the subcohorts.
Gene Expression Analysis
Gene expression was quantified for samples in the DASL cohort
before initiation of this project as follows. Centrally extracted
mRNA specimens were profiled using the Illumina Whole-
Genome DASL protocol for expression profiling with Illumina
HT-12 v4 BeadArray platform for FFPE samples (under the direc-
tion of S.W. and B.L.-J.) at Florida Scripps. Gene expression val-
ues were cubic spline normalized with no background correction
using BeadStudio software (Illumina). The natural logarithms of
microarray probe expression values were used in this analysis.
Expression values for probes other than the five used to com-
pute EarlyR were not available for this project. Access to these
data may be requested through the IBCSG data-sharing process.
Computation of EarlyR Score and Risk Strata
Expression values for the EarlyR panel genes were obtained
from the Illumina DASL assay data for the study cohort using
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the same Illumina probes used to compute EarlyR in the
METABRIC cohort (9), specifically ESPL1 (ILMN_1742145), MKI67
(ILMN_1734827), SPAG5 (ILMN_2141259), PLK1 (ILMN_1736176),
and PGR (ILMN_1811014). The EarlyR score (0–100) was com-
puted for each sample as described in the Supplementary
Methods (available online). This computation was performed
(by SA Buechler) blinded to the patients’ clinical data. The
EarlyR risk strata were subsequently defined using predeter-
mined thresholds (9) as follows: EarlyR-Low (EarlyR 25),
EarlyR-Int (EarlyR >25 to  75), and EarlyR-High (EarlyR >75).
Study Endpoints
To investigate the prognostic feature of EarlyR with disease out-
comes, the analysis endpoints included DRFI, defined as time
from randomization to breast cancer recurrence at a distant
site, and BCFI, defined as time from randomization to first inva-
sive breast cancer recurrence at a local, regional, or distant site
or invasive contralateral breast cancer. Both endpoints were
censored at the minimum of last disease follow-up, death or
8 years since diagnosis, in an attempt to focus on the assess-
ment of “early” prognostic features of EarlyR. Eight years was
chosen as a threshold based on a prior publication showing that
the prognostic utility of current genomic signatures for ERþ
breast cancer deteriorates after 8 years (13).
Statistical Analysis of Disease Outcomes
Sampling weights were computed as described above. Weighted
analysis methods (generalized Horvitz-Thompson methods) were
used to adjust estimates of recurrence-free interval test statistics
to obtain unbiased analyses and to give consistent estimates of
prognosis in the full ERþ cohort. In the weighted analyses, contri-
butions to Kaplan-Meier estimators and tests were weighted pro-
portional to the inverses of the sampling fractions; special
methods were used to compute variances (14). Weighted Kaplan-
Meier estimates of DRFI and BCFI distributions were calculated.
From weighted Cox regression, stratified by chemotherapy and
treatment assignment, hazard ratios with 95% confidence inter-
vals were estimated, and stratified log-rank trend test statistics
with 1 degree of freedom for comparing the three EarlyR risk strata
were reported. Similar analyses were used in the exploratory anal-
yses of ERþ/LN, ERþ/LNþ, and ERþ/HER2 subcohorts.
Statistical power was assessed based on the overall ERþ co-
hort (N¼ 1174) and the endpoint of BCFI, the endpoint that
guided the case-cohort sampling. Due to the case-cohort design,
an adjusted standard error estimate for the coefficient of inter-
est (ie, EarlyR three risk strata as a continuous variable) was
obtained using the weighed Cox regression model. The standard
error was subsequently used to assess statistical power to de-
tect a difference (hazard ratio) comparing two adjacent EarlyR
groups based on a trend test. Assuming a two-sided significance
level of .05, there was a 90% power to detect a hazard ratio of
1.33 for comparing two adjacent EarlyR risk strata.
Results were presented in accordance with REporting recom-
mendations for tumour MARKer prognostic studies criteria (15).
All statistical tests were two-sided. No multiple comparison
adjustments were implemented, and P values less than .05 in the
overall EarlyR cohort were considered statistically significant.
Results
Patient Characteristics
Unweighted distributions of clinical features of the EarlyR cohort
(N¼ 1174) were consistent with those of patients enrolled in the
BIG 1–98 intention-to-treat population, when considering the
case-cohort sampling design (Table 1; Supplementary Table 1,
available online). The characteristics of the EarlyR cohort and the
three additional analysis subgroups (ERþ/LN [n¼ 547], ERþ/LNþ
[n¼ 610], and ERþ/ HER2 [n¼ 1098]) are summarized in Table 1.
In the EarlyR cohort, approximately 30% were assigned to each
monotherapy arm and 40% to sequential treatment arms.
Chemotherapy was administered to 17% of the LN and 51% of
the LNþ patients. HER2 positivity was 6%. Within 8 years of ran-
domization, the frequencies of DRFI events reported for the ERþ,
ERþ/LN, ERþ/LNþ, and ERþ/HER2 subgroups were 14%, 10%,
17%, and 13%, respectively, and the frequencies of BCFI events
reported were 18%, 15%, 21%, and 17%, respectively, for the EarlyR
cohort and the three analysis subgroups.
ER+/HER2-
N = 1098
ER+/LN+
N = 610
ER+/LN-
N = 547
BIG 1-98, hormone receptor-posive  
ITT, N = 8010
RNA material available
N = 2538
DASL cohort
(case-cohort sampling)
N = 1218 (257 cases of recurrence)
Excluded unknown LN 
N = 17
EarlyR cohort
(confirmed ER+)
N = 1174 (216 cases of recurrence)
Excluded  tumors not ER+
on central tesng 
N = 44
Excluded HER2+
N = 76
Figure 1. Flow diagram for defining the EarlyR cohort and analytic subgroups. DASL ¼ Illumina’s cDNA-mediated annealing, selection, extension, and ligation; EarlyR ¼
a prognostic risk score defined using the selected five genes (ESPL1, SPAG5, MKI67, PLK1, and PGR) panel; ERþ ¼ estrogen receptor–positive; ITT ¼ intention to treat; LNþ
¼ lymph node–positive; LN ¼ lymph node–negative.
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Unweighted Distribution of EarlyR
In the primary EarlyR cohort of all ERþ breast cancer patients
(N¼ 1174), EarlyR score (Figure 2A) classified 67% of patients as
low risk (EarlyR-Low), 19% as intermediate risk (EarlyR-Int), and
14% as high risk (EarlyR-High). In the secondary analysis
subgroups (ERþ/LN [N¼ 547], ERþ/LNþ [N¼ 610], and ERþ/
HER2 [N¼ 1098]), EarlyR-Low contained 65–70% of patients,
Table 1. Characteristics of the overall EarlyR cohort and analytic subgroups (unweighted distributions)*
Characteristic ERþ (N¼1174) ER+/LN (N¼ 547) ER+/LN+ (N¼ 610) ER+/HER2 (N¼1098)
Treatment assignment, No. (%)
Letrozole 333 (28) 163 (30) 164 (27) 301 (27)
Tamoxifen 362 (31) 180 (33) 176 (29) 339 (31)
Sequential 479 (41) 204 (37) 270 (44) 458 (42)
Age, median (IQR), y 61 (56–68) 62 (56–68) 61 (55–68) 62 (56–68)
Mastectomy, No. (%) 417 (36) 154 (28) 260 (43) 383 (35)
Prior chemotherapy, No. (%) 403 (34) 93 (17) 310 (51) 368 (34)
Tumor size >2 cm, No. (%) 465 (40) 164 (30) 296 (49) 426 (39)
Tumor grade, 2 or 3, No. (%) 992 (85) 448 (82) 529 (87) 916 (84)
Lymph node positive, No. (%) 610 (53) 0 (0) 610 (100) 573 (53)
ER positive, No. (%) 1174 (100) 547 (100) 610 (100) 1098 (100)
HER2-, No. (%) 1098 (94) 511 (93) 573 (94) 1098 (100)
Ki-67 LI of immunostained cells, median (IQR), % 13 (7–21) 12 (7–21) 14 (8–20) 12 (7–20)
Recurrences, No. (%)
8 y breast cancer event 216 (18) 84 (15) 127 (21) 190 (17)
8 y distance recurrence 163 (14) 55 (10) 104 (17) 145 (13)
EarlyR risk group, No. (%)
EarlyR-Low 792 (67) 383 (70) 396 (65) 756 (69)
EarlyR-Int 161 (14) 61 (11) 99 (16) 141 (13)
EarlyR-High 221 (19) 103 (19) 115 (19) 201 (18)
*EarlyR-High (75 < EarlyR), EarlyR-Int (25 < EarlyR  75), and EarlyR-Low (EarlyR  25); IQR ¼ interquartile range.
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Figure 2. EarlyR continuous score is plotted vs quantiles of the score for analytical cohorts (A) ER+, (B) ER+/LN, (C) ER+/LN+, (D) ER+/HER2 in this study. The three
EarlyR risk groups, defined with predetermined thresholds of 25 and 75, are indicated by color. In each cohort, the low-risk group (EarlyR 25) contains at least 65% of
patients, and the intermediate-risk group (EarlyR >25 to 75) contains less than 20% of patients. EarlyR ¼ a prognostic risk score defined using the selected five genes
(ESPL1, SPAG5, MKI67, PLK1, and PGR) panel; ERþ ¼ estrogen receptor–positive; LNþ ¼ lymph node–positive; LN ¼ lymph node–negative.
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EarlyR-High contained 11–16% of patients, and EarlyR-Int con-
tained 18–19% of patients (Figure 2B–D; Table 1). These distribu-
tions were computed for the actual subgroups and were not
weighted estimates.
EarlyR and Risk of Distant Recurrence and Breast Cancer
Recurrence in the ER1 Group
The EarlyR stratification was statistically significantly prognos-
tic of DRFI in the overall ERþ cohort (Figure 3A; Ptrend¼ .008)
within 8 years of randomization; specifically, with weighted
HR¼ 1.73 (95% CI ¼ 1.14 to 2.64) comparing EarlyR-High vs
EarlyR-Low or HR¼ 1.35 (95% CI ¼ 0.91 to 2.0) comparing EarlyR-
Int vs EarlyR-Low. The percent free of distant recurrence at
8 years was estimated as 91% (95% CI ¼ 89% to 92%) for EarlyR-
Low and 84% (95% CI ¼ 80% to 88%) for EarlyR-High. The contin-
uous EarlyR score was also statistically significantly prognostic.
Specifically, for a 10-unit increase of EarlyR risk score, we ob-
served an HR¼ 1.07 (95% CI ¼ 1.03 to 1.12) for DRFI. In a multi-
variable model adjusting for age, LN status, tumor size, grade,
and Ki-67 labeling index, we observed an HR¼ 1.03 (95% CI ¼
0.99 to 1.08) for EarlyR risk score.
Similarly, the EarlyR risk stratification was prognostic of
BCFI within 8 years (Figure 3B, Ptrend¼ .002, HR¼ 1.74, 95% CI ¼
1.21 to 2.52 comparing EarlyR-High vs EarlyR-Low; HR¼ 1.37,
95% CI ¼ 0.97 to 1.94 comparing EarlyR-Int vs EarlyR-Low). The
percent estimated free of breast cancer recurrence at 8 years
was 87% (95% CI ¼ 86% to 89%) for EarlyR-Low and 79% (95% CI
¼ 75% to 84%) for EarlyR-High. Also, a continuous EarlyR score is
prognostic of BCFI with HR¼ 1.07 (95% CI ¼ 1.03 to 1.11) for a 10-
unit increase in the EarlyR risk score.
EarlyR and Recurrence in Subgroups of ER1 Breast
Cancer
As exploratory analyses, we assessed the early (within 8 years)
prognostic value of EarlyR in subsets of this ERþ cohort. The
EarlyR risk stratification was shown to be prognostic of DRFI in
ERþ/HER2 (N¼ 1098, Ptrend¼ .03; Figure 4C; and similar trends
were also observed in ERþ/LN (N¼ 547, Ptrend¼ .05; Figure 4A)
and ERþ/LNþ (N¼ 610, Ptrend¼ .08; Figure 4B). EarlyR was also
observed to be prognostic of BCFI (Figure 4D–F) in each sub-
group. Results were consistent for ERþ/LN/HER2 (N¼ 511,
DRFI Ptrend¼ .089).
EarlyR and Recurrence in ER1/LN2 Patients Not Treated
with Chemotherapy
The principal application of prognostic signatures such as Oncotype
DX and EarlyR is to discriminate between ERþ/LN breast cancer
patients who have sufficiently high risk of relapse to justify
treating with chemotherapy and those with good prognosis
who are unlikely to benefit from chemotherapy. In the BIG 1–
98 trial, chemotherapy treatment was at the discretion of the
treating physician. To assess whether physicians left
untreated some high-risk patients, we evaluated the prognos-
tic significance of EarlyR in the ERþ/LN patients with no prior
chemotherapy treatment (N¼ 454 of 547). In this subgroup of
patients, the estimated 8-year DRFI was 95.4% (95% CI ¼ 94% to
96.8%) in EarlyR-Low (N¼ 334) and 88.5% (95% CI ¼ 82.7% to
94.6%) in EarlyR-High (N¼ 44), as shown in Figure 5A. EarlyR
was likewise prognostic of BCFI (Figure 5B) in this subgroup.
Because most of these patients were HER2 (N¼ 433), results
were consistent in the ERþ/LN/HER2 subgroup.
Treatment and Recurrence by EarlyR Stratum
In the BIG 1–98 clinical trial, DRFI was statistically significantly
improved with letrozole vs tamoxifen monotherapy (12). There
were too few events in the EarlyR cohort to properly assess for
differential treatment effects by EarlyR stratification. The esti-
mated DRFI as of 8 years was observed to be higher in the letro-
zole monotherapy arm than that in the tamoxifen monotherapy
arm in both EarlyR-Low (Supplementary Figure 1, available on-
line; N¼ 471, 93.3% vs 88.0%) and EarlyR-High (Supplementary
Figure 1, available online; N¼ 89, 86.1% vs 79.4%).
Discussion
Clinical trials such as BIG 1-98 have shown the benefit of hor-
mone therapy to treat early-stage ERþ breast cancer in post-
menopausal women. Although the majority of early-stage ERþ
breast cancer patients remain disease-free when treated with
only tamoxifen or an aromatase inhibitor, as many as 20% suf-
fer a distant recurrence within 10 years of diagnosis.
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Figure 3. Weighted Kaplan-Meier (KM) estimates of (A) distant recurrence–free
interval (DRFI) and (B) breast cancer–free interval (BCFI) according to EarlyR risk
strata in the overall EarlyR estrogen receptor–positive (ERþ) cohort. CI ¼ confi-
dence interval; EarlyR ¼ a prognostic risk score defined using the selected five
genes (ESPL1, SPAG5, MKI67, PLK1, and PGR) panel; HR ¼ hazard ratio; LNþ ¼
lymph node positive; LN ¼ lymph negative.
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Increasingly, multi-gene signatures have proven to be more ef-
fective than clinico-pathological traits alone in identifying those
ERþ patients who are at a high risk of recurrence and may bene-
fit from cytotoxic chemotherapy in addition to hormone
therapy.
The EarlyR genomic signature was shown to be prognostic of
DRFI and BCFI in the METABRIC ERþ cohort and of distant
metastasis–free survival in multiple other cohorts, independent
of clinico-pathological features (9). However, in these prior stud-
ies, gene expression was measured from fresh-frozen tissues
of samples of convenience, and patient treatments may not
have matched current standard of care. It was therefore neces-
sary to validate the gene signature in a randomized clinical trial
cohort.
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Figure 4. Weighted Kaplan-Meier (KM) estimates of distant recurrence–free interval (DRFI) (A–C) and breast cancer–free interval (BCFI) (D–F) according to EarlyR risk
strata in the analytic subgroups ERþ (estrogen receptor–positive) lymph node–negative (LN) (A) DRFI, (D) BCFI; ERþ lymph node–positive (LNþ) (B) DRFI, (E) BCFI, and
ERþ HER2 (C) DRFI, (F) BCFI. CI ¼ confidence interval; EarlyR ¼ a prognostic risk score defined using the selected five genes (ESPL1, SPAG5, MKI67, PLK1, and PGR)
panel; HR ¼ hazard ratio.
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In the current study, we validated the prognostic signifi-
cance of EarlyR in a case-cohort sample (N¼ 1174) of BIG 1-98 in
which all patients were prescribed endocrine therapy for
5 years. Importantly, mRNA was extracted from FFPE tissues in
a single laboratory using standardized protocol and subse-
quently assayed to measure gene expression.
A strength of this study is the independence of the computa-
tion of EarlyR score and strata (Buechler lab), blind to clinical
data, from gene expression analysis (Avera Cancer Institute)
and statistical analysis (IBCSG Statistical Center). Importantly,
the thresholds defining the risk strata were prospectively de-
fined, again blind to clinical data, satisfying the criteria for a
prospective study using archived samples defined by Simon et
al. (16). The study used a case-cohort design to maximize the
use of available samples and a weighted analysis method to
give unbiased estimates of prognostic significance of EarlyR in
the full ERþ BIG 1-98 study population.
EarlyR was previously shown by concordance index analysis
to have comparable prognostic significance to surrogates of the
Oncotype DX Recurrence Score, ROR, and Mammaprint. In this
study, prognosis for the EarlyR-Low patients in the overall ERþ
postmenopausal breast cancer cohort was excellent, with the
estimated 8-year DRFI being 91% (95% CI ¼ 89% to 92%), and in
ERþ/LN patients not treated with chemotherapy the estimated
8-year DRFI was 95.4% (95% CI ¼ 94% to 96.8%) and estimated 8-
year BCFI was 92.5% (95% CI ¼ 90.8% to 94.3%). This low rate of
distant recurrence is comparable with the distant recurrence
rates of the low-risk patients identified by Oncotype DX and
PAM50 ROR in the translational protocol of the Arimidex,
Tamoxifen, Alone, or in Combination (transATAC) cohort of the
ATAC trial (17). In ERþ/LN patients in this study, EarlyR classi-
fied 70% as low risk and 11% as high risk. In contrast, in the
ERþ/LN patients from transATAC, Oncotype DX classified 59%
as low risk and 10% as high risk, and ROR classified 58% as low
risk and 16% as high risk (17). These results build on earlier evi-
dence (9) that EarlyR has comparable or superior prognostic sig-
nificance to these existing assays while offering a definitive
prognosis for more patients.
The risk strata defined for Oncotype DX, ROR, and other tests
were selected based on evaluation of candidate thresholds of
each test’s continuous score in a training cohort. These differ-
ent methods naturally lead to some discordance, although in
most studies, 50–60% of patients were classified as low risk by
each test. In contrast, the risk strata for EarlyR were defined by
intrinsic features of the panel genes (Supplementary Methods,
available online). In the TAILORx trial, the patients with a recur-
rence score less than 26 (86%) had an estimated DRFI of approxi-
mately 95% after 9 years when treated with hormone therapy
alone. The high percentage of TAILORx patients who had good
prognosis and did not benefit from chemotherapy is consistent
with the definition of a large low-risk stratum by EarlyR.
EarlyR was previously shown to predict the benefit of add-
ing neoadjuvant chemotherapy to hormone therapy (11). The
ability of EarlyR to predict adjuvant chemotherapy benefit was
not assessed in this study because chemotherapy treatment
was not randomized in BIG 1–98. Further studies are needed to
determine if EarlyR-High patients are likely to benefit from che-
motherapy. As a preliminary step, we showed here that among
those ERþ/LN patients not treated with chemotherapy,
EarlyR-High patients had poorer prognosis than EarlyR-Low
patients.
There are a number of limitations of this study, the principle
one being that the gene signature was computed with gene ex-
pression data from DASL-whole genome analysis. Although a
specific quantitative reverse transcription–polymerase chain
Reaction assay has been developed, it was deemed more pru-
dent to use available gene expression data for this study rather
than reassaying valuable tissue. Furthermore, due to the case-
cohort design of the DASL cohort, hazard ratios and recurrence-
free probabilities were estimated using weighted analysis rather
than from the whole trial population.
In conclusion, this study confirmed the prognostic signifi-
cance of the EarlyR signature for postmenopausal patients with
ERþ breast cancer assessed using FFPE tissues from a cohort of
the BIG 1–98 randomized clinical trial of adjuvant endocrine
therapy. Within each analytical subgroup, the EarlyR signature
identified a large set (EarlyR-Low, at least 65%) of patients with
excellent prognosis and comparably few patients (at most 19%)
with intermediate risk. Moreover, in the patients identified as
low risk by EarlyR, there was less than 5% risk of distant recur-
rence at 8 years in the ERþ/LN patients not treated with che-
motherapy. Additional studies are needed to determine
whether patients identified as high risk by EarlyR are likely to
benefit from chemotherapy.
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Figure 5. Weighted Kaplan-Meier (KM) estimates of (A) distant recurrence–free
interval (DRFI) and (B) breast cancer–free interval (BCFI) according to EarlyR risk
strata in estrogen receptor–positive (ERþ) lymph node negative (LN) patients
not receiving chemotherapy. CI ¼ confidence interval; EarlyR ¼ a prognostic risk
score defined using the selected five genes (ESPL1, SPAG5, MKI67, PLK1, and PGR)
panel; HR ¼ hazard ratio.
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